Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 6Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1

Interventions

Carboplatin 98Cisplatin 95pembrolizumab 90Gemcitabine 81Paclitaxel 80Docetaxel 73Capecitabine 64Oxaliplatin 53Specimen Handling 51Fluorouracil 51Magnetic Resonance Spectroscopy 49Radiotherapy 48Bevacizumab 48Dexamethasone 45Cyclophosphamide 44Leucovorin 38Drug Therapy 38Irinotecan 36Doxorubicin 36Pemetrexed 35Injections 30Trastuzumab 28Vincristine 27Rituximab 27Radiosurgery 25Prednisone 25Etoposide 25130-nm albumin-bound paclitaxel 25Radiation 24Lenalidomide 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × 5-aminolevulinic acid hexyl ester × Clear all
NCT06525571 2025-11-18

Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

Johns Hopkins University

Phase 3 Recruiting
200 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡